ClinicalTrials.gg

Acne Vulgaris clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 792 studies for Acne Vulgaris across more than 10 countries. 93 are recruiting or about to start. 742 of them are mainly about Acne Vulgaris (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,012 studies for Acne Vulgaris. How that becomes 790 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Acne Vulgaris, and those it files under no condition that list Acne Vulgaristhemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,012Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −222Match it another way5 name it in the title, 1 in a keyword, and 216 by a synonym or other text the search reads.
  3. 790The count on this page8 of them list Acne Vulgaris in their own words; the registry filed them under no condition.

Status

Completed
559
Status unknown
75
Recruiting
45
Not yet recruiting
45
Terminated
24
Active, not recruiting
20

Phase

Phase 2
142
Phase 3
138
Phase 4
124
Phase 1
105
Early Phase 1
15

Where

United States
373
Canada
58
Egypt
39
China
35
Poland
24
France
24

Who develops what

Add Acne Vulgaris to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 18 programs from 15 companies, 17 with this as their studies’ main aim; 4 with a live phase 3 study; 7 primary completions in the next 12 months. Compare Sanofi, Sun Pharmaceutical Industries and 3SBio here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
trifaroteneRecent, limited
Evidence
  • NCT05550337 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “AKLIEF®” · registered Sep 2022
Galderma Group AG69% of its industry studiesUS: Galderma Group AG (FDA 2019)11 study
AdapaleneEarlier only
Evidence
  • NCT04329403 · aurobindo pharma · Phase 3 · comparator · “Differin 0.1% Topical Gel” · registered Mar 2020
  • NCT03650361 · aleor dermaceuticals limited · Phase 3 · comparator · “Differin 0.3% Topical Gel” · registered Aug 2018
  • NCT03615768 · Lee's Pharmaceutical Limited · Phase 3 · comparator · “Adapalene Gel” · registered Jul 2018
  • NCT02525549 · Padagis LLC · Phase 3 · comparator · “Adapalene and Benzoyl Peroxide Gel (Reference)” · registered Aug 2015
  • NCT00964223 · GlaxoSmithKline · Phase 4 · comparator · “benzoyl peroxide and adapalene gel (EPIDUO™ Gel)” · registered Aug 2009
Galderma Group AG51% of its industry studiesUS: off-patent, 19 generics marketed00 studies
ClindamycinEarlier only
Evidence
  • NCT03615768 · Lee's Pharmaceutical Limited · Phase 3 · comparator · “Clindamycin Gel” · registered Jul 2018
  • NCT02616614 · Teva Pharmaceutical Industries, Ltd. · Phase 3 · comparator · “Onexton” · registered Nov 2015
  • NCT02515305 · Padagis LLC · Phase 3 · comparator · “Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)” · registered Jul 2015
  • NCT00664248 · Bausch Health Companies Inc. · Phase 3 · comparator · “Clindamycin” · registered Apr 2008
  • NCT00663286 · Bausch Health Companies Inc. · Phase 3 · comparator · “Clindamycin” · registered Apr 2008
GlaxoSmithKline43% of its industry studiesUS: off-patent, 8 generics marketed00 studies

5 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
trifaroteneApproved: US 2019☆ Track1 live phase-3 study: NCT07186413Galderma Group AG
Cyproterone Acetate☆ Track1 live phase-3 study: NCT06905210Eurofarma Laboratorios S.A.
denifanstat☆ Track1 live phase-3 study: NCT07863193Sagimet Biosciences Inc.
ClascoteroneApproved: US 2020 · EU 2025☆ Track2 live phase-3 studies: NCT07457294, NCT064035013SBio Inc.

The 4 in phase 3 with the nearest primary completion, of 18 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (7)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.trifarotene · Galderma Group AG · Phase 3 main aimNCT07186413 A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris — primary endpoint: Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at Week 12 · 561 enrolled
  • Feb 2027 est.Cyproterone Acetate · Eurofarma Laboratorios S.A. · Phase 3 main aimNCT06905210 Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris — primary endpoint: Absolute reduction from baseline in the number of inflammatory acne lesions assessed at Cycle 6. · 531 enrolled
  • 28 Feb 2027 est.Klenzit®-C (Adapalene/Clindamycin Phosphate Gel) · IR INNOVATE RESEARCH PRIVATE LIMITED · Phase 4 main aimNCT07918001 Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris — primary endpoint: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs and SAEs, and AEs Leading to Discontinuation · 225 enrolled

4 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Acne Vulgaris studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Mineralocorticoid receptor antagonists (MRAs) 1 open

Coming up

37studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger. 20 (44%) take children under 18. 5 (11%) are for women only and 0 (0%) for men only; 16 (36%) take healthy volunteers.

Recruiting studies that take each age, of 45
AgeWomenMen
104 (9%)4 (9%)
1842 (93%)38 (84%)
3041 (91%)38 (84%)
4037 (82%)33 (73%)
5026 (58%)25 (56%)
6519 (42%)19 (42%)
7516 (36%)16 (36%)
8516 (36%)16 (36%)

Across all 792 studies, recruiting or not: 63% stop at 75 or younger and 61% at 65; 58% take children; 7% are for women only and 2% for men only; 34% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Acne Vulgaris studies take

Of 62 phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo2–10 · 51 studies4 mo1–7 · 44 studies—
Phase 1/216 mo6–22 · 13 studies——
Phase 29 mo6–15 · 37 studies9 mo6–15 · 29 studies—
Phase 313 mo10–17 · 62 studies13 mo10–17 · 53 studies—
Phase 411 mo7–16 · 45 studies——
Interventional, no phase9 mo4–19 · 120 studies9 mo3–19 · 62 studies9 mo4–17 · 58 studies
Observational10 mo3–13 · 37 studies8 mo3–11 · 22 studies—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 792. Browse all 792 → or search them.